Damora Therapeutics (DMRA) Return on Capital Employed (2020 - 2026)
Damora Therapeutics posted quarterly Return on Capital Employed of 63.9% for Q1 2026, up 6661.0% year-on-year from 0.95% in Q1 2025, and up 64.99% on a QoQ basis from 182.52% in Q4 2025.
Damora Therapeutics (DMRA) has 7 years of Return on Capital Employed data on file, last reported at 63.9% in Q1 2026.
- For the quarter ending Q1 2026, Return on Capital Employed rose 6661.0% year-over-year to 63.9%; the trailing twelve-month figure through Mar 2026 stood at 63.9% (up 6661.0% YoY), and the FY2025 full-year result was 177.61%, down 9354.0% from the prior year.
- Return on Capital Employed for Q1 2026 stood at 63.9%, up from 182.52% in the prior quarter.
- Across five years, Return on Capital Employed topped out at 51.32% in Q1 2022 and bottomed at 182.52% in Q4 2025.
- The 5-year median for Return on Capital Employed is 104.09% (2023), against an average of 107.29%.
- The widest annual swing landed in 2025, when Return on Capital Employed tumbled 7439 bps; it then surged 6661 bps in 2026.
- A 5-year view of Return on Capital Employed shows it stood at 92.04% in 2022, then decreased by 13 bps to 104.09% in 2023, then slipped by 12 bps to 116.83% in 2024, then sank by 56 bps to 182.52% in 2025, then soared by 65 bps to 63.9% in 2026.
- The last three Return on Capital Employed figures came in at 63.9% (Q1 2026), 182.52% (Q4 2025), and 169.73% (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | ROCE (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | 450.31% |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 51.73% |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | -107.40% |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 21.10% |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 10.19% |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 20.34% |
| 10 | Damora Therapeutics | 853.36 Mn | 650.97 Mn | - | -63.90% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -63.90% |
| Dec 31, 2025 | -182.52% |
| Sep 30, 2025 | -169.73% |
| Jun 30, 2025 | -142.20% |
| Mar 31, 2025 | -130.51% |
| Dec 31, 2024 | -116.83% |
| Sep 30, 2024 | -95.34% |
| Jun 30, 2024 | -101.47% |
| Mar 31, 2024 | -103.61% |
| Dec 31, 2023 | -104.09% |
| Sep 30, 2023 | -111.79% |
| Jun 30, 2023 | -110.64% |
| Mar 31, 2023 | -105.31% |
| Dec 31, 2022 | -92.04% |
| Sep 30, 2022 | -77.86% |
| Jun 30, 2022 | -64.74% |
| Mar 31, 2022 | -51.32% |
| Dec 31, 2021 | -41.93% |
| Sep 30, 2021 | -36.92% |
| Jun 30, 2021 | -31.95% |
| Mar 31, 2021 | -25.92% |
| Dec 31, 2020 | -26.02% |